Modifications are coming in 2026 for GLP-1 medication.
Lengthy outlined by excessive costs, shortages and weekly injections, medication together with Wegovy and Zepbound are anticipated to be simpler to entry and afford. And new choices for individuals averse to needles are coming.
“The GLP-1 panorama is anticipated to broaden considerably,” mentioned Dr. Christopher McGowan, a gastroenterologist who runs a weight reduction clinic in Cary, North Carolina. “For the primary time, medical weight problems therapy will transfer away from a one-size-fits-all mannequin.”
Weight reduction tablets
GLP-1 tablets for weight reduction might mark probably the most vital shift but.
Final month, Novo Nordisk received Meals and Drug Administration approval for the primary GLP-1 capsule for weight reduction. The remedy, marketed because the Wegovy capsule, is anticipated to be broadly accessible this month.
One other GLP-1 capsule, from Eli Lilly, is anticipated to realize approval later this 12 months.
Dr. Shauna Levy, medical director of the Tulane Weight Loss Middle, mentioned the tablets shall be an awesome choice for sufferers preferring oral drugs or who’ve struggled to entry the injectable variations.
“With a lot product available in the market, I hope the competitors will additional cut back costs,” Levy mentioned.
A month’s provide of the tablets is anticipated to be cheaper than a month’s provide of injections.
Novo Nordisk hasn’t introduced the record value for the Wegovy capsule but, however it has mentioned that the 2 lowest doses will value $149 a month for individuals paying in money and never utilizing insurance coverage. The bottom dose of the Wegovy injection, by comparability, is $349 a month for individuals paying in money.
Beginning Monday, the 2 greater doses of the tablets shall be priced at $299 a month for individuals paying in money. For these with insurance coverage that covers the medication, out-of-pocket prices might be as little as $25 a month, in accordance with the corporate.
Dr. Daniela Hurtado Andrade, an endocrinologist on the Mayo Clinic in Jacksonville, Florida, mentioned the decrease costs will most definitely broaden entry. Nonetheless, she famous, probably the most drastic weight reduction within the trials got here from the very best dose, which suggests individuals would possible must pay extra in the event that they need to lose extra weight.
Even $149 a month for some continues to be too costly, she mentioned.
“It’s one thing that must be mentioned with sufferers,” Andrade mentioned, “as a result of they might have expectations that aren’t actual.”
Levy mentioned that one downside to the capsule is that it should be taken on a strict schedule to get the perfect outcomes: each morning on an empty abdomen. In a late-stage medical trial, individuals who adhered to the schedule misplaced 16.6% of their physique weight, on common. That fell to 13.6% when individuals didn’t take the capsule precisely as prescribed.
“I believe we have to contemplate that the efficacy of those drugs is decreased if they don’t seem to be taken persistently, and I’m curious to see how they carry out in actual life,” Levy mentioned. There’s a bit extra flexibility round Lilly’s capsule, which nonetheless should be taken day by day however will be taken any time of the day.
Chris Mertens, 35, of Menominee Falls, Wisconsin, mentioned he had no hassle remembering to take the Wegovy capsule each morning, which he did as a part of a medical trial in late 2022. Although he didn’t realize it on the time, he bought the actual remedy, not a placebo.
When he started the trial, he weighed about 260 kilos, with a physique mass index of round 32, and hoped to get nearer to 200 kilos. After a 12 months and a half on the remedy, Mertens mentioned he misplaced about 40 kilos, finally plateauing at round 220. The load loss, he mentioned, gave him extra vitality at work and at dwelling and altered his relationship with meals.
A stronger injection
Lilly is getting nearer to ending its medical trials on what might be probably the most highly effective GLP-1 drug but, known as retatrutide.
Like Wegovy and Zepbound, retatrutide is a weekly injection. It targets GLP-1 and GIP, the identical two hormones focused by Lilly’s blockbuster medication Mounjaro and Zepbound. Retatrutide additionally targets a 3rd hormone, known as glucagon, which can additional increase weight reduction.
Lilly mentioned in December that in a Section 3 medical trial, sufferers taking the very best dose of the experimental injection misplaced practically 29% of their physique weight on common after about 16 months — greater than has been seen with any GLP-1 drug at present available on the market.
The trial included roughly 450 adults with weight problems or who had been obese and had knee osteoarthritis.
“These are numbers we merely didn’t assume had been potential just some years in the past,” McGowan mentioned.
The remedy’s excessive effectiveness, nonetheless, might include a tradeoff of extra intense unwanted side effects, equivalent to nausea, diarrhea, constipation and vomiting. Lilly reported a dropout charge of 18.2% for sufferers who bought the drug in contrast with 4% within the placebo group. By comparability, the dropout charge for the very best dose group in a separate trial for Zepbound was simply 6.2%.
“Extra shouldn’t be all the time higher,” McGowan mentioned. “In real-world observe, these discontinuation charges could also be even greater.”
Andrade mentioned the remedy might be useful for individuals with extreme weight problems, who should have hassle losing a few pounds on the present GLP-1 drugs, though she’d prefer to see extra knowledge on the unwanted side effects.
A Lilly spokesperson mentioned the corporate is finishing seven further trials on retatrutide, that are anticipated to be accomplished in 2026. It might file for FDA approval as early as this 12 months.
Costs and partnerships
Entry to the medication has additionally expanded by way of cash-pay applications.
Lilly first began providing money reductions for sure doses of Zepbound in 2024, by way of its LillyDirect program. Novo Nordisk later adopted with NovoCare Pharmacy in March, promoting Wegovy at a reduced value for money payers.
In 2025, some main retailers adopted. Costco in October introduced it might promote Wegovy and Ozempic for $499 a month for patrons paying money, and Walmart has rolled out a comparable association with Lilly for Zepbound.
In 2026, the Trump administration will launch the self-pay platform TrumpRx.gov. The web site is not going to promote prescribed drugs straight however will join individuals to drugmakers’ low cost web sites.
The typical month-to-month value of weight reduction injections on TrumpRx is anticipated to begin round $350 and fall to about $250 inside the subsequent two years, President Donald Trump mentioned when asserting the preparations with the drugmakers. Beginning doses of GLP-1 tablets are anticipated to value $149.
Dr. Susan Spratt, professor of drugs at Duke College Faculty of Medication, mentioned the partnerships will “solely enhance entry.” The query, she added, is whether or not the reductions shall be sufficient to enhance entry to everybody who may benefit from the drugs. “They’re nonetheless fairly costly,” Spratt mentioned.
Levy mentioned the self-pay choices would make the medication simpler to get, significantly for individuals whose insurance coverage doesn’t cowl them.
Most of the self-pay choices join sufferers with docs on telehealth who will decide in the event that they qualify for the medication and write a prescription.
“I believe there may be potential for elevated entry with offers for cheaper merchandise at Walmart and Costco,” Levy mentioned, “however I actually need to be certain that sufferers are handled and are adopted by weight problems drugs specialists or suppliers who actually know what they’re doing with anti-obesity drugs.”
Marina Kopf contributed.
